We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanostart AG: Successful Exit in the US
News

Nanostart AG: Successful Exit in the US

Nanostart AG: Successful Exit in the US
News

Nanostart AG: Successful Exit in the US

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanostart AG: Successful Exit in the US"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nanostart holding BioMicro has sold its remaining assets for a profit to US diagnostics company IRIS for 3.2 million US dollars. The asset sold is an analysis product line that automatically performs high-performance tests on the genetic material of somatic cells.

With this transaction, the remaining assets of BioMicro have now been successfully sold. In March of this past year, BioMicro sold its main product – the entire MAUI system line – to global leader Roche within the framework of an asset deal. A portion of revenues from the transaction will be entered as net income on the 2010 annual financial statement. The remaining portion will be applied to the first half of 2011.

With an 8.4 percent holding in BioMicro, Nanostart will receive a corresponding disbursement from the transaction. Upon completion of the upcoming payments, the exit of BioMicro from the Nanostart portfolio will have reached a successful conclusion.

Nanostart CEO Marco Beckmann observes: "The shareholding in this highly innovative company has paid off for us. The transaction marks yet another successful exit and confirms our position as the world's leading nanotechnology investor. With the sale of BioMicro assets to a life science company, Nanostart has achieved its objective."
Advertisement